TES & tDCS: What the Peer-Reviewed Literature Says
Transcranial electrical stimulation across neurological, psychiatric, and developmental conditions — safety data, adult evidence base, and what is known in pediatric populations
Section 1
TES Safety: What the Evidence Actually Shows
Safety is the most fundamental question before any discussion of efficacy. The cumulative TES safety literature — across tDCS, tACS, and tRNS — is now substantial, and the findings are consistent: when used within established parameters, TES carries no serious adverse events in either adults or children.
Common minor effects (self-limited, resolve within minutes): tingling or itching under electrodes, brief skin redness, mild scalp headache in a small percentage of sessions. No serious neurological adverse events have been documented at standard parameters (1–2 mA, 20–30 min, conventional pad or HD-tDCS electrodes).
Relative contraindications requiring physician review before use: implanted metal or electronic devices near the head, uncontrolled seizure disorder, open skull defect, pregnancy, and certain cardiac conditions. Children under 8 years have limited dedicated safety data.
Section 2
Adult Indications: Where the Evidence Is Strongest
The most robust clinical evidence for tDCS efficacy is in adults. These three indications — depression, chronic pain, and stroke rehabilitation — have the largest RCT databases, the most replicated effect sizes, and in the case of depression, active regulatory pathway discussions. They are relevant context for understanding what TES can achieve when the evidence base matures.
Major Depressive Disorder
Depression has the largest and most replicated tDCS evidence base of any condition. A 2025 JAMA Network Open meta-analysis of 88 RCTs (5,522 participants) found tDCS consistently associated with superior outcomes versus sham across MDD, depression with psychiatric comorbidities, and depression with medical comorbidities. The canonical protocol — anodal left DLPFC (F3), cathodal right DLPFC (F4) — directly targets the left hypoactivation/right hyperactivation asymmetry well-established in imaging studies of MDD.
Home-based tDCS is now a near-clinical reality. A 2024 Nature Medicine Phase 2 RCT (Woodham et al., N=174, 10 weeks of supervised self-administration) and a 2024 JAMA Psychiatry RCT (Borrione et al.) both confirmed efficacy for acute depressive episodes outside a clinical setting. A 2025 UCLA RCT in JAMA Network Open demonstrated that MRI-guided HD-tDCS with individualized electrode placement outperforms sham with a clinically meaningful effect size.
88 RCTs · 5,522 participants · Home delivery validatedChronic Pain
Chronic pain — including fibromyalgia, central sensitization syndromes, and neuropathic pain — is among the most consistent adult responders to tDCS. The primary motor cortex (M1) anodal protocol, which mirrors the rationale for invasive motor cortex stimulation, produces meaningful pain reduction in fibromyalgia and complex regional pain syndrome in multiple sham-controlled trials. Multiple meta-analyses (including a 2021 Cochrane-style review of 42 RCTs) confirm significant analgesic effects beyond placebo, particularly for conditions with central sensitization.
The DLPFC target is also explored for the affective-motivational dimension of chronic pain, particularly in patients with comorbid depression or catastrophizing, where prefrontal neuromodulation addresses both pain processing and mood simultaneously.
42+ RCTs · M1 and DLPFC protocols · Fibromyalgia, neuropathic painStroke Rehabilitation
Post-stroke motor and language rehabilitation is one of the earliest and best-characterized tDCS indications. Bihemispheric protocols (anodal over perilesional motor cortex + cathodal over contralesional M1) reduce transcallosal inhibition and facilitate use-dependent plasticity during concurrent physiotherapy. A 2021 Cochrane review of 44 RCTs found significant improvements in upper limb motor function, though heterogeneity in timing, severity, and lesion location continues to complicate meta-analytic conclusions.
For post-stroke aphasia, anodal stimulation to Broca's area or the broader left language network combined with speech-language therapy shows consistent gains in naming speed and fluency. The window of maximal benefit appears to be subacute stroke (days to weeks post-ictus) when neural reorganization is most active.
44 RCTs (Cochrane) · Motor + language · Best in subacute phaseSection 3
Pediatric & Developmental Conditions: Condition-by-Condition Review
ADHD
The dominant protocol targets the dorsolateral prefrontal cortex (DLPFC) — the hub of executive function — with anodal stimulation over the left F3 position. A 2025 meta-analysis pooled seven RCTs (290 patients) and found that active tDCS significantly reduced impulsivity (SMD = −0.60) and inattention (SMD = −1.00) versus sham. A 2025 systematic review of 11 controlled adult studies (415 participants) confirmed domain-specific improvements in inattention and inhibitory control, though heterogeneity in protocols remains a challenge.
Children and adolescents represent a growing subgroup. A 2025 pediatric-focused meta-analysis found favorable effect sizes on parent-rated symptoms immediately post-treatment. The right inferior frontal gyrus has also been explored as a target for impulsivity with less consistent results.
Ataxia
Cerebellar tDCS is scientifically coherent: the cerebellum is accessible to transcranial current and central to motor coordination and adaptation. A meta-analysis (Chen et al., Cerebellum, 2021) pooled five RCTs and found a 26% improvement in ataxia rating scores post-treatment, sustained at three months. A 2023 sham-controlled RCT in Movement Disorders demonstrated anodal cerebellar tDCS reduced motor and cognitive symptoms in Friedreich's Ataxia specifically. A 2024 three-way crossover trial compared cerebellar tDCS, tACS, and sham — both active modalities outperformed sham on wearable gait sensors.
Protocol: 2 mA anodal over posterior fossa, 10–20 consecutive sessions. A combined cerebello-spinal approach is under active multicenter investigation.
Autism Spectrum Disorder (ASD)
ASD is the best-studied pediatric psychiatric tDCS indication. A 2021 meta-analysis (16 studies) found improvements in social and behavioral domains with anodal left DLPFC stimulation. A 2023 triple-arm double-blind RCT (Han et al., Autism, N=105 adolescents aged 14–21) found 10 days of prefrontal tDCS plus cognitive remediation produced significant SRS-2 improvements (effect size d = 0.61–0.88). A 2024 network meta-analysis of 14 NIBS interventions found anodal tDCS over left DLPFC was the only intervention reaching statistical significance versus sham (SMD = −1.40). A 2025 RCT evaluated HD-tDCS in ASD with sensory abnormalities, showing gains in social awareness.
A comprehensive 2025 systematic review (PubMed through March 2025, 11 RCTs in meta-analysis, 28 in review) confirms the positive trend across studies.
Brain Injury & Disorders of Consciousness
tDCS over the DLPFC may activate frontoparietal networks underlying conscious awareness and command-following. Early open-label studies showed behavioral improvement on the Coma Recovery Scale-Revised (CRS-R). A 2022 individual patient data meta-analysis (Annals of Neurology, 5 RCTs) found no significant group-level effect, though subgroup analysis favored minimally conscious state over vegetative state, and traumatic over anoxic etiology.
Cerebral Palsy
In unilateral spastic CP, the contralesional hemisphere may hyperexcite and suppress the affected hemisphere via transcallosal inhibition. Bihemispheric tDCS (anodal ipsilesional M1 + cathodal contralesional M1) addresses this directly. A landmark 2025 meta-analysis (Developmental Medicine & Child Neurology, Kim et al.) found anodal M1 tDCS significantly improved motor function in children with CP, with amplification when paired with task-specific therapy. A 2025 systematic review from Guangzhou found meaningful GMFM gains with combined tDCS + rehabilitation.
Depression
Depression has the most mature TES evidence base of any condition. See Section 2 above for a full summary of adult RCT data (88 RCTs, 5,522 participants, home-based delivery validated). A 2024–2025 home-tDCS meta-analysis in Scientific Reports further confirmed home delivery for depressive disorders with robust safety data. The convergence of telehealth supervision and consumer-grade hardware is making home-based treatment a near-term clinical reality for adults.
For youth depression, a May 2025 PRISMA review identified 14 eligible registered or published studies through November 2024. Two trials showed substantial symptom improvement in adolescents and young adults (ages 16–25), but recruitment challenges and methodological limitations mean the youth evidence base is not yet comparable to the adult data.
Dyslexia
Developmental dyslexia involves disrupted phonological processing linked to atypical left temporoparietal activation — a region that anodal tDCS can target directly. A 2022 crossover RCT (Bambino Gesù, Rome) showed a short intensive tDCS course significantly improved non-word reading speed at one-month follow-up versus sham. A 2025 scoping review confirmed that tDCS combined with phonological training produces gains in decoding speed and text fluency. A 2024 TES review in Child: Care, Health and Development included tRNS as an emerging modality for learning disabilities alongside tDCS. Concurrent stimulation + training consistently outperforms stimulation alone.
Long COVID (PASC)
Neuropsychiatric PASC — cognitive fog, fatigue, attention impairment — maps onto prefrontal circuit dysfunction, making tDCS a logical candidate. The NIH RECOVER-NEURO trial (5-arm, 22 sites, August 2023–June 2024, published JAMA 2025) randomized cognitive long COVID patients to BrainHQ + tDCS versus multiple comparators, with meaningful cognitive gains in the tDCS arm. A 2025 Brain Stimulation RCT found repetitive anodal prefrontal tDCS significantly reduced fatigue scores versus sham. A 2024 Czech NIMH sham-controlled trial (N=33) found both active and sham groups improved, highlighting high placebo response rates in this population.
Evidence at a Glance
| Condition | Evidence Level | Primary Population in Trials | Notable Anchor Study |
|---|---|---|---|
| Depression (adult) | Strongest | Adults · Youth emerging | 88-RCT meta-analysis, JAMA (2025) |
| Chronic Pain (adult) | Strong | Adults | 42-RCT Cochrane-style review (2021) |
| Stroke Rehab (adult) | Strong | Adults | 44-RCT Cochrane review (2021) |
| Cerebral Palsy | Promising | Children | Meta-analysis, DMCN (2025) |
| Autism (ASD) | Promising | Adolescents · Limited <10yo data | 11-RCT meta-analysis (2025) |
| ADHD | Promising | Adults · Adolescents | 7-RCT meta-analysis, 290 pts (2025) |
| Ataxia | Promising | Adults | 5-RCT meta-analysis (2021) |
| Dyslexia | Promising | Children (8–14) | Scoping review + RCTs (2025) |
| Brain Injury / DoC | Mixed | Adults | IPD meta-analysis, 5 RCTs (2022) |
| Long COVID | Emerging | Adults | RECOVER-NEURO, JAMA (2025) |
The TES literature has matured considerably since this library launched in 2019. Adult depression, chronic pain, and stroke rehabilitation now have the strongest evidence. Cerebral palsy and ASD are the pediatric indications with the most actual pediatric trial data. For conditions where most evidence comes from adults — ataxia, brain injury, long COVID, depression in those under 16 — clinical application in children requires individualized judgment and should not proceed from adult evidence alone. I will continue updating the PubMed literature collections as evidence accumulates.
— Dr. Josh Rotenberg
Board-Certified Pediatric Neurologist | Epilepsy | Sleep Medicine
Neurology & Sleep Specialists, PLLC · Houston, TX · myspecialist.clinic
No comments:
Post a Comment